|

CABA-201 Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Pipeline

Phase 1/2: 2

Top Sponsors

  • Cabaletta Bio2

Indications

  • Lupus Nephritis1
  • Systemic Lupus Erythematosus1
  • Lupus1
  • Generalized Myasthenia Gravis (gMG)1
  • Cancer1

Orange, California2 trials

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

University of California Irvine

Phase 1/2
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

University of California Irvine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.